He · The Journal of neuroscience : the official journal of the Society for Neuroscience 2005 · Preclinical animal and cell-culture experiment · n=?

Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption.

Cited 183 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Preclinical animal and in vitro laboratory study

PubMed 15659598 · doi:10.1523/JNEUROSCI.3959-04.2005 · record verified 2026-08-28

What was done

The authors evaluated the effect of ibogaine on ethanol self-administration in rats using two-bottle choice and operant self-administration paradigms, including a relapse model. To identify the underlying mechanism, they microinjected ibogaine into the ventral tegmental area (VTA) or substantia nigra, measured midbrain glial cell line-derived neurotrophic factor (GDNF) expression after systemic ibogaine administration, and tested GDNF pathway activation (phosphorylation of Ret and ERK1) in dopaminergic neuron-like SHSY5Y cells. They also tested whether intra-VTA microinjection of GDNF mimicked, and intra-VTA anti-GDNF neutralizing antibodies blocked, ibogaine's effect on ethanol intake.

What was found

The abstract reports directional findings without numerical values or effect sizes. Ibogaine decreased rat ethanol intake in two-bottle choice, operant self-administration, and relapse models. Microinjection of ibogaine into the VTA, but not the substantia nigra, decreased ethanol self-administration. Systemic ibogaine increased GDNF expression in a midbrain region including the VTA, and ibogaine upregulated GDNF pathway signaling in SHSY5Y cells via increased phosphorylation of Ret and ERK1. Intra-VTA GDNF microinjection mimicked ibogaine's reduction of ethanol intake, and intra-VTA anti-GDNF neutralizing antibodies reduced the ibogaine-mediated effect.

Why it matters

This study identifies midbrain GDNF upregulation as a key molecular mechanism mediating ibogaine's reduction of alcohol self-administration in rodents. This points to GDNF signaling as a target for developing alcoholism therapeutics that avoid the adverse side effects of ibogaine.

Limits

The study is restricted to rodent models and cell culture, precluding direct conclusions about human safety or efficacy. The abstract reports no sample sizes, quantitative data, statistical values, or effect sizes. Adverse effects, potential toxicity, and long-term durability of the intervention were not reported in the abstract.

Cited by